Pitfalls, prevention, and treatment of hyperuricemia during tumor lysis syndrome in the era of rasburicase (recombinant urate oxidase)

Biologics: Targets and Therapy

Volumn 2, Issue 1, 2008, Pages 129-141

  Pession, Andrea ^a   Melchionda, Fraia ^a   Castellini, Claudia ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Allopurinol; Rasburicase; Tumor lysis syndrome; Urate oxidase; Uric acid

Indexed keywords

EID: 57349158696     PISSN: 11775475     EISSN: 11775491     Source Type: Journal    
DOI: 10.2147/btt.s1522     Document Type: Review

References (53)

1. Alkhuja S, Ulrich H. 2002. Acute renal failure from spontaneous acute tumor lysis syndrome: a case report and review. Ren Fail, 24:227-32
2. Andreoli SP, Clark JH, McGuire WA, et al. 1986. Purine excretion during tumor lysis in children with acute lymphocytic leukemia receiving allopurinol: relationship to acute renal failure. J Pediatr, 109292-8
3. Annemans L, Moeremans K, Lamotte M, et al. 2003. Incidence, medical resource utilisation and costs of hyperuricemia and tumour lysis syndrome in patients with acute leukaemia and non-Hodgkin's lymphoma in four European countries. Leuk Lymphoma, 44:77-83
4. Barton JC. 1989. Tumor lysis syndrome in nonhematopoietic neoplasms. Cancer, 64:738-40
5. Bayol A, Capdevielle J, Malazzi P, et al. 2002. Modifi cation of a reactive cysteine explains differences between rasburicase and Uricozyme, a natural Aspergillus flavus uricase. Biotechnol Appl Biochem, 36:21-31
6. Bedrna JPJ. 1929. Akuter harnleiterverschluss nach bestrahlung chronischer leukamien mit rontgenstrahlen. Med Klin, 25:1700-1
7. Browning LA, Kruse JA. 2005. Hemolysis and methemoglobinemia secondary to rasburicase administration. Ann Pharmacother, 39:1932-5
8. Cairo MS, Bishop M. 2004. Tumour lysis syndrome: new therapeutic strategies and classifi cation. Br J Haematol, 127:3-11
9. Cammalleri L, Malaguarnera M. 2007. Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout. Int J Med Sci, 4:83-93
10. Cheson BD, Dutcher BS. 2005. Managing malignancy-associated hyperuricemia with rasburicase. J Support Oncol, 3:117-24
11. Coutinho AK, De OSM, Pinczowski H, et al. 1997. Tumor lysis syndrome in a case of chronic lymphocytic leukemia induced by high-dose corticosteroids. Am J Hematol, 54:85-6
12. Feld, J., Mehta, H, Burkes, RL. 2000. Acute spontaneous tumor lysis syndrome in adenocarcinoma of the lung: a case report. Am J Clin Oncol, 23, 491-3
13. Filler G. 2001. Acute renal failure in children: aetiology and management. Paediatr Drugs, 3:783-92
14. Flombaum CD. 2000. Metabolic emergencies in the cancer patient. Semin Oncol, 27:322-34
15. Friedman TB, Polanco GE, Appold JC, et al. 1985. On the loss of uricolytic activity during primate evolution-I. Silencing of urate oxidase in a hominoid ancestor. Comp Biochem Physiol B, 81:653-9
16. Goldman SC, Holcenberg JS, Finklestein JZ, et al. 2001. A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood, 97:2998-3003
17. Habib GS, Saliba WR. 2002. Tumor lysis syndrome after hydrocortisone treatment in metastatic melanoma: a case report and review of the literature. Am J Med Sci, 323:155-7
18. Holdsworth MT, Nguyen P. 2003. Role of i.v. allopurinol and rasburicase in tumor lysis syndrome. Am J Health Syst Pharm, 60:2213-22; quiz 2223-4
19. Hsu HH, Chan YL, Huang CC. 2004. Acute spontaneous tumor lysis presenting with hyperuricemic acute renal failure: clinical features and therapeutic approach. J Nephrol, 17:50-6
20. Hsu HH, Huang CC. 2004. Acute spontaneous tumor lysis in anaplastic large T-cell lymphoma presenting with hyperuricemic acute renal failure. Int J Hematol, 79:48-51
21. Hummel M, Buchheidt D, Reiter S, et al. 2005. Recurrent chemotherapyinduced tumor lysis syndrome TLS. with renal failure in a patient with chronic lymphocytic leukemia-successful treatment and prevention of TLS with low-dose rasburicase. Eur J Haematol, 75:518-21
22. Hutcherson DA, Gammon DC, Bhatt MS, et al. 2006. Reduced-dose rasburicase in the treatment of adults with hyperuricemia associated with malignancy. Pharmacotherapy, 26:242-7
23. Jasek AM, Day HJ. 1994. Acute spontaneous tumor lysis syndrome. Am J Hematol, 47:29-31
24. Jeha S, Pui CH. 2005. Recombinant urate oxidase rasburicase. in the prophylaxis and treatment of tumor lysis syndrome. Contrib Nephrol, 147:9-79
25. Larosa C, McMullen L, Bakdash S, et al. 2007. Acute renal failure from xanthine nephropathy during management of acute leukemia. Pediatr Nephrol, 22:32-5
26. Leplatois P, Le Douarin B, Loison G. 1992. High-level production of a peroxisomal enzyme: Aspergillus fl avus uricase accumulates intracellularly and is active in Saccharomyces cerevisiae. Gene, 122:39-45
27. Lim E, Bennett P, Beilby J. 2003. Sample preparation in patients receiving uric acid oxidase rasburicase therapy. Clin Chem, 49:417-9
28. Liu CY, Sims-McCallum RP, Schiffer CA. 2005. A single dose of rasburicase is suffi cient for the treatment of hyperuricemia in patients receiving chemotherapy. Leuk Res, 29:63-5
29. Locatelli F, Rossi F. 2005. Incidence and pathogenesis of tumor lysis syndrome. Contrib Nephrol, 147:1-8
30. Mahmoud HH, Leverger G, Patte C, et al. 1998. Advances in the management of malignancy-associated hyperuricaemia. Br J Cancer, 77(Suppl 4):8-20
31. Masera G, Jankovic M, Zurlo MG, et al. 1982. Urate-oxidase prophylaxis of uric acid-induced renal damage in childhood leukemia. J Pediatr, 100:52-5
32. McDonnell AM, Lenz KL, Frei-Lahr DA, et al. 2006. Single-dose rasburicase 6 mg in the management of tumor lysis syndrome in adults. Pharmacotherapy, 26:806-12
33. Navolanic PM, Pui CH, Larson RA, et al. 2003. Elitek-rasburicase: an effective means to prevent and treat hyperuricemia associated with tumor lysis syndrome, a Meeting Report, Dallas, Texas, January 2002. Leukemia, 17:499-514
34. Oldfi eld V, Perry CM. 2006. Spotlight on rasburicase in anticancer therapyinduced hyperuricemia. BioDrugs, 20:197-9
35. Parham WA, Mehdirad AA, Biermann KM, et al. 2006. Hyperkalemia revisited. Tex Heart Inst J, 33:40-7
36. Patte C, Sakiroglu C, Ansoborlo S, et al. 2002. Urate-oxidase in the prevention and treatment of metabolic complications in patients with B-cell lymphoma and leukemia, treated in the Societe Francaise d'Oncologie Pediatrique LMB89 protocol. Ann Oncol, 13:789-95
37. Pea F. 2005. Pharmacology of drugs for hyperuricemia. Mechanisms, kinetics and interactions. Contrib Nephrol, 147:35-46
38. Pession A, Barbieri E. 2005. Treatment and prevention of tumor lysis syndrome in children. Experience of Associazione Italiana Ematologia Oncologia Pediatrica. Contrib Nephrol, 147:80-92
39. Pui, CH. 2002. Rasburicase: a potent uricolytic agent. Expert Opin Pharmacother, 3:433-42
40. Pui CH, Jeha S, Irwin D, et al. 2001a. Recombinant urate oxidase rasburicase. in the prevention and treatment of malignancy-associated hyperuricemia in pediatric and adult patients: results of a compassionate-use trial. Leukemia, 15:1505-9
41. Pui CH, Mahmoud HH, Wiley JM, et al. 2001b. Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients with leukemia or lymphoma. J Clin Oncol, 19:697-704
42. Pui CH, Relling MV, Lascombes F, et al. 1997. Urate oxidase in prevention and treatment of hyperuricemia associated with lymphoid malignancies. Leukemia, 11:1813-6
43. Ribeiro RC, Pui CH. 2003. Recombinant urate oxidase for prevention of hyperuricemia and tumor lysis syndrome in lymphoid malignancies. Clin Lymphoma, 3:225-32
44. Riccio B, Mato A, Olson EM, et al. 2006. Spontaneous tumor lysis syndrome in acute myeloid leukemia: two cases and a review of the literature. Cancer Biol Ther, 5:1614-7
45. Sparano J, Ramirez M, Wiernik PH. 1990. Increasing recognition of corticosteroid-induced tumor lysis syndrome in non-Hodgkin's lymphoma. Cancer, 65:1072-3
46. Stark ME, Dyer MC, Coonley CJ. 1987. Fatal acute tumor lysis syndrome with metastatic breast carcinoma. Cancer, 60:762-4
47. Tarella C, Bono D, Zanni M, et al. 2005. Intensive chemotherapy in patients with lymphoma. Management of the risk of hyperuricemia. Contrib Nephrol, 147:93-104
48. Tomlinson GC, Solberg LA Jr. 1984. Acute tumor lysis syndrome with metastatic medulloblastoma. A case report. Cancer, 53:1783-5
49. Trifi lio S, Gordon L, Singhal S, et al. 2006. Reduced-dose rasburicase recombinant xanthine oxidase. in adult cancer patients with hyperuricemia. Bone Marrow Transplant, 37:997-1001
50. Turtureanu-Hanganu E. 2002. Emergency care: the tumor lysis syndrome. Rev Med Chir Soc Med Nat Iasi, 106:705-11
51. Ueng S. 2005. Rasburicase Elitek.: a novel agent for tumor lysis syndrome. Proc Bayl Univ Med Cent, 18:275-9
52. Wossmann W, Schrappe M, Meyer U, et al. 2003. Incidence of tumor lysis syndrome in children with advanced stage Burkitt's lymphoma/leukemia before and after introduction of prophylactic use of urate oxidase. Ann Hematol, 82:160-5
53. Yeldandi AV, Yeldandi V, Kumar S, et al. 1991. Molecular evolution of the urate oxidase-encoding gene in hominoid primates: nonsense mutations. Gene, 109:281-4.